Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Depression: Overview01:18

Depression: Overview

331
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
331
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Long-term Depression01:03

Long-term Depression

2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
2.6K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

165
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
165
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

208
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
208
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

741
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
741

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Generalizable structure-function covariation predictive of antidepressant response revealed by target-oriented multimodal fusion.

Nature. Mental health·2026
Same author

Precise strategies for targeted elimination of senescent cells to combat aging and age-related diseases.

Acta biomaterialia·2026
Same author

Positive and negative affect influence learning during exposure therapy: Secondary analysis from a randomized controlled trial.

Journal of anxiety disorders·2026
Same author

"Doing Our Best:" A Qualitative Study of Researcher Challenges Administering Neuromodulation Across Different Phenotypes.

AJOB neuroscience·2026
Same author

Personalized Network-Guided Neuromodulation Enhances Human Working Memory.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Dual Mechanisms of crRNA 3'-Extension-Mediated Cas12a Attenuation Enable Programmable One-Pot CRISPR Diagnostics.

Analytical chemistry·2026

関連する実験動画

Updated: Sep 9, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

174

鬱病の治療に関連する脳の変化:メタ解析

Gianna M Perez1, Benjamin M Rosenberg2, Wenyi Xu3

  • 1Center for Brain Imaging and Stimulation, Center for Neuromodulation in Depression and Stress Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

NeuroImage. Clinical
|August 31, 2025
PubMed
まとめ

うつ病の効果的な治療は 脳の重要な領域である右桃体の活動を 一貫して減少させます この発見は,重度のうつ病の治療の進行を追跡するためのバイオマーカーの開発に役立ちます.

キーワード:
アミグダラバイオマーカーうつ病鬱病の治療メタ解析fMRI

さらに関連する動画

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

791
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.7K

関連する実験動画

Last Updated: Sep 9, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

174
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

791
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.7K

科学分野:

  • 神経イメージング
  • 精神科の研究
  • 脳活動

背景:

  • 治療後の脳の変化を理解することは 精神医学における神経イメージングの進歩に不可欠です
  • 研究は主に患者対対照群の違いに焦点を当てており,うつ病治療後の患者内での変化に重点が置かれていません.
  • この研究は,共通の神経メカニズムを特定するために,様々な治療法での発見を合成します.

研究 の 目的:

  • うつ病治療の研究の座標ベースのメタ分析を行う.
  • 治療前のおよび後の活動変化を示す一般的な脳領域を特定する.
  • 鬱病に対する様々な治療介入における 共通の治療メカニズムを探求する.

主な方法:

  • メタ解析の有効化確率評価 (ALE) を利用した.
  • 18件の実験で302人のデータを 含めたものです
  • 薬理学,心理療法,ECT,プシロシビン,ケタミンを含む研究から集約されたタスクベースのfMRIデータ.

主要な成果:

  • 右桃体は 研究で一貫した変化の領域として 特定されました
  • 右桃体のピークMNI座標は [30, 2, -22] で報告されています.
  • うつ病の治療に効果があることが分かりました

結論:

  • fMRIで測定された 鬱の治療反応における 右桃体の重要性を強調しています
  • 治療効果を追跡するための 潜在的イメージングバイオマーカーとして右桃体を示唆しています
  • 神経イメージングに基づく将来のうつ病バイオマーカー研究のための焦点を当てた領域を提供します.